Teverelix
Prostate Cancer (High CV Risk Patients)
Key Facts
About Antev
Antev is a Phase III-ready biotech focused on developing Teverelix, a GnRH antagonist, for specific, high-risk patient populations in prostate cancer and acute urinary retention. The company has a lean, experienced leadership team with deep expertise in clinical development and CMC, positioning it to advance its registration-ready data package. Its strategy targets clear medical needs in men's health where current treatments pose significant cardiovascular risks, aiming for a differentiated market entry.
View full company profileAbout Antev
Antev is a Phase III-ready biotech focused on developing Teverelix, a GnRH antagonist, for specific, high-risk patient populations in prostate cancer and acute urinary retention. The company has a lean, experienced leadership team with deep expertise in clinical development and CMC, positioning it to advance its registration-ready data package. Its strategy targets clear medical needs in men's health where current treatments pose significant cardiovascular risks, aiming for a differentiated market entry.
View full company profile